PT-101

N/A

Report date: 2026/03/19 20:00:18

Base Information

Drug NamePT-101
Drug Alias NamePT-101MK-6194PT101
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment
Mechanisms of ActionInterleukin-2 receptor alpha chain agonists
TargetsInterleukin-2 receptor alpha chain
Therapy Area/IndicationsVitiligoLupus Erythematosus, SystemicDermatitis, Atopic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaCanada +[30] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPandion Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme LLCMSD R&D（China）Co Ltd
Inactive CompaniesN/A
Active IndicationsDermatitis, AtopicColitis, Ulcerative
Inactive IndicationsVitiligoLupus Erythematosus, Systemic

Other Information

ATC CodeN/A
Related LinksN/A